MANF Protects the Retina in two Additional Models
Post# of 30025
Posted On: 10/06/2014 9:36:00 PM
MANF Protects the Retina in two Additional Models of RP
Crxtvrm65 RP model
Rd1 RP model
Studies performed by Drs. Joana Neves, Henri Jasper and Deepak Lamba ; The Buck Institute for Aging
http://content.stockpr.com/amarantus/media/aa...64655e.pdf (Slide 10)
Less than two months ago...
August 11, 2014 - http://www.buckinstitute.org/buck-news/amaran...laboration
“We are very pleased to be working with Amarantus on this exciting MANF project,” said Henri Jasper, PhD, professor at the Buck Institute for Research on Aging. “Novel aspects of the biology of MANF are beginning to be uncovered, and I believe working with Amarantus is the best way to coalesce the scientific understanding of MANF and to move the Program forward towards multiple therapeutic applications.”
Under the terms of the agreements, Amarantus has agreed to fund research by Jasper, and his Buck faculty colleague Deepak Lamba, PhD, and Postdoctoral Fellow Joanna Neves, PhD , to further their scientific insights and generation of intellectual property regarding the therapeutic potential of MANF. In addition, the Company has acquired an exclusive option to license said intellectual property.
Crxtvrm65 RP model
Rd1 RP model
Studies performed by Drs. Joana Neves, Henri Jasper and Deepak Lamba ; The Buck Institute for Aging
http://content.stockpr.com/amarantus/media/aa...64655e.pdf (Slide 10)
Less than two months ago...
August 11, 2014 - http://www.buckinstitute.org/buck-news/amaran...laboration
“We are very pleased to be working with Amarantus on this exciting MANF project,” said Henri Jasper, PhD, professor at the Buck Institute for Research on Aging. “Novel aspects of the biology of MANF are beginning to be uncovered, and I believe working with Amarantus is the best way to coalesce the scientific understanding of MANF and to move the Program forward towards multiple therapeutic applications.”
Under the terms of the agreements, Amarantus has agreed to fund research by Jasper, and his Buck faculty colleague Deepak Lamba, PhD, and Postdoctoral Fellow Joanna Neves, PhD , to further their scientific insights and generation of intellectual property regarding the therapeutic potential of MANF. In addition, the Company has acquired an exclusive option to license said intellectual property.
(0)
(0)